PERLICH IRENE enters NGM BIOPHARMACEUTICALS INC with 10K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 9/18/2023ACC: 0001209191-23-049797
Officer· Principal Accounting Officer
Since Sep 2023
10K
Baseline shares
100% direct
10K
Direct ownership
1 position
132.50K
Derivative underlying
4 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned10K
Total
10K direct10K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 10K | Direct |
| Total | 10K | 10K direct |
Derivative Holdings4
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
35K
Shares owned
N/A
Exercise price
15.20
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
30K
Shares owned
N/A
Exercise price
4.36
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
50K
Shares owned
N/A
Exercise price
29.62
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
17.50K
Shares owned
N/A
Exercise price
5.36
Expiration
—
Exercise window
—
Total
Underlying
132.50K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 15.20 | — | — | 35K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 4.36 | — | — | 30K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 29.62 | — | — | 50K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 5.36 | — | — | 17.50K | N/A |
| Total | 132.50K | 0.00 | ||||